nach oben

Current Cardiology Reports

Erschienen in:

01.11.2014 | Cardiovascular Genomics (R McPherson, Section Editor)

Unlocking the Door to New Therapies in Cardiovascular Disease: MicroRNAs Hold the Key

verfasst von: My-Anh Nguyen, Denuja Karunakaran, Katey J Rayner

Erschienen in: Current Cardiology Reports | Ausgabe 11/2014

Einloggen, um Zugang zu erhalten

Abstract

MicroRNAs are the most abundant class of regulatory noncoding RNA and are estimated to regulate over half of all human protein-coding genes. The heart is comprised of some of the most complex and highly conserved genetic networks and is thus under tight regulation by post-transcriptional mechanisms. MicroRNAs (miRNAs) have been found to regulate virtually all aspects of cardiac physiology and pathophysiology, from the development of inflammatory atherosclerosis to hypertrophic remodeling in heart failure. Owing to the wide-spread involvement of miRNAs in the development of and protection from many diseases, there has been increasing excitement surrounding their potential as novel therapeutic targets to treat and prevent the worldwide epidemic of cardiovascular disease.

Chilton RJ. Pathophysiology of coronary heart disease: a brief review. J Am Osteopath Assoc. 2004;104(9 Suppl 7):S5–8.PubMed

Cholesterol Treatment Trialists C, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670–81. doi:10.1016/S0140-6736(10)61350-5.CrossRef

Ecker JR, Bickmore WA, Barroso I, Pritchard JK, Gilad Y, Segal E. Genomics: ENCODE explained. Nature. 2012;489(7414):52–5. doi:10.1038/489052a.

Hata A. Functions of microRNAs in cardiovascular biology and disease. Annu Rev Physiol. 2013;75:69–93. doi:10.1146/annurev-physiol-030212-183737.PubMedCrossRef

Condorelli G, Latronico MVG, Cavarretta E. microRNAs in cardiovascular diseases: current knowledge and the road ahead. J Am Coll Cardiol. 2014;63(21):2177–87. doi:10.1016/j.jacc.2014.01.050.

Moore KJ, Tabas I. Macrophages in the pathogenesis of atherosclerosis. Cell. 2011;145(3):341–55. doi:10.1016/j.cell.2011.04.005.PubMedPubMedCentralCrossRef

Feig JE. Regression of atherosclerosis: insights from animal and clinical studies. Ann Glob Health. 2014;80(1):13–23. doi:10.1016/j.aogh.2013.12.001.PubMedCrossRef

Najafi-Shoushtari SH, Kristo F, Li Y, Shioda T, Cohen DE, Gerszten RE, et al. MicroRNA-33 and the SREBP host genes cooperate to control cholesterol homeostasis. Science. 2010;328(5985):1566–9. doi:10.1126/science.1189123.PubMedCrossRef

Rayner KJ, Suarez Y, Davalos A, Parathath S, Fitzgerald ML, Tamehiro N, et al. MiR-33 contributes to the regulation of cholesterol homeostasis. Science. 2010;328(5985):1570–3. doi:10.1126/science.1189862.PubMedPubMedCentralCrossRef

10.

Gerin I, Clerbaux LA, Haumont O, Lanthier N, Das AK, Burant CF, et al. Expression of miR-33 from an SREBP2 intron inhibits cholesterol export and fatty acid oxidation. J Biol Chem. 2010;285(44):33652–61. doi:10.1074/jbc.M110.152090.PubMedPubMedCentralCrossRef

11.

Horie T, Ono K, Horiguchi M, Nishi H, Nakamura T, Nagao K, et al. MicroRNA-33 encoded by an intron of sterol regulatory element-binding protein 2 (Srebp2) regulates HDL in vivo. Proc Natl Acad Sci U S A. 2010;107(40):17321–6. doi:10.1073/pnas.1008499107.PubMedPubMedCentralCrossRef

12.

Marquart TJ, Allen RM, Ory DS, Baldan A. miR-33 links SREBP-2 induction to repression of sterol transporters. Proc Natl Acad Sci U S A. 2010;107(27):12228–32. doi:10.1073/pnas.1005191107.PubMedPubMedCentralCrossRef

13.

Rayner KJ, Sheedy FJ, Esau CC, Hussain FN, Temel RE, Parathath S, et al. Antagonism of miR-33 in mice promotes reverse cholesterol transport and regression of atherosclerosis. J Clin Invest. 2011;121(7):2921–31. doi:10.1172/jci57275.PubMedPubMedCentralCrossRef

14.

Horie T, Baba O, Kuwabara Y, Chujo Y, Watanabe S, Kinoshita M, et al. MicroRNA-33 deficiency reduces the progression of atherosclerotic plaque in ApoE-/- mice. J Am Heart Assoc. 2012;1(6):e003376. doi:10.1161/JAHA.112.003376.PubMedPubMedCentralCrossRef

15.

Rotllan N, Ramirez CM, Aryal B, Esau CC, Fernandez-Hernando C. Therapeutic silencing of MicroRNA-33 inhibits the progression of atherosclerosis in Ldlr-/- mice. Arterioscler, Thromb, Vasc Biol. 2013. doi:10.1161/ATVBAHA.113.301732.

16.

Rayner KJ, Esau CC, Hussain FN, McDaniel AL, Marshall SM, van Gils JM, et al. Inhibition of miR-33a/b in non-human primates raises plasma HDL and lowers VLDL triglycerides. Nature. 2011;478(7369):404–7. doi:10.1038/nature10486.PubMedPubMedCentralCrossRef

17.

de Aguiar Vallim TQ, Tarling EJ, Kim T, Civelek M, Baldan A, Esau C, et al. MicroRNA-144 regulates hepatic ATP binding cassette transporter A1 and plasma high-density lipoprotein after activation of the nuclear receptor farnesoid X receptor. Circ Res. 2013;112(12):1602–12. doi:10.1161/CIRCRESAHA.112.300648.PubMedPubMedCentralCrossRef

18.

Ramirez CM, Rotllan N, Vlassov AV, Davalos A, Li M, Goedeke L, et al. Control of cholesterol metabolism and plasma high-density lipoprotein levels by microRNA-144. Circ Res. 2013;112(12):1592–601. doi:10.1161/CIRCRESAHA.112.300626.PubMedPubMedCentralCrossRef

19.

Ramirez CM, Davalos A, Goedeke L, Salerno AG, Warrier N, Cirera-Salinas D, et al. MicroRNA-758 regulates cholesterol efflux through posttranscriptional repression of ATP-binding cassette transporter A1. Arterioscler, Thromb, Vasc Biol. 2011;31(11):2707–14. doi:10.1161/ATVBAHA.111.232066.CrossRef

20.

Hu Y-W, Hu Y-R, Zhao J-Y, Li S-F, Ma X, Wu S-G, et al. An agomir of miR-144-3p accelerates plaque formation through impairing reverse cholesterol transport and promoting pro-inflammatory cytokine production. PLoS One. 2014;9(4):e94997. doi:10.1371/journal.pone.0094997.PubMedPubMedCentralCrossRef

21.

Lagos-Quintana M, Rauhut R, Yalcin A, Meyer J, Lendeckel W, Tuschl T. Identification of tissue-specific microRNAs from mouse. Curr Biol. 2002;12(9):735–9. doi:10.1016/S0960-9822(02)00809-6.

22.

Krutzfeldt J, Rajewsky N, Braich R, Rajeev KG, Tuschl T, Manoharan M, et al. Silencing of microRNAs in vivo with ‘antagomirs’. Nature. 2005;438(7068):685–9. doi:10.1038/nature04303.PubMedCrossRef

23.

Elmen J, Lindow M, Schutz S, Lawrence M, Petri A, Obad S, et al. LNA-mediated microRNA silencing in non-human primates. Nature. 2008;452(7189):896–9. doi:10.1038/nature06783.PubMedCrossRef

24.

Esau C, Davis S, Murray SF, Yu XX, Pandey SK, Pear M, et al. miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab. 2006;3(2):87–98. doi:10.1016/j.cmet.2006.01.005.

25.

Jopling CL, Schutz S, Sarnow P. Position-dependent function for a tandem microRNA miR-122-binding site located in the hepatitis C virus RNA genome. Cell Host Microbe. 2008;4(1):77–85. doi:10.1016/j.chom.2008.05.013.PubMedPubMedCentralCrossRef

26.

Jopling CL, Yi M, Lancaster AM, Lemon SM, Sarnow P. Modulation of hepatitis C virus RNA abundance by a liver-specific microRNA. Science. 2005;309(5740):1577–81. doi:10.1126/science.1113329.PubMedCrossRef

27.••

Janssen HL, Reesink HW, Lawitz EJ, Zeuzem S, Rodriguez-Torres M, Patel K, et al. Treatment of HCV infection by targeting microRNA. N Engl J Med. 2013;368(18):1685–94. doi:10.1056/NEJMoa1209026. The phase 2a results of miravirsen, an inhibitor against miR-122, in patients with hepatitis C virus. These are the most advanced clinical studies with anti-microRNA therapies and will pave the way for future miRNA-based therapeutics.PubMedCrossRef

28.•

Soh J, Iqbal J, Queiroz J, Fernandez-Hernando C, Hussain MM, Soh J, et al. MicroRNA-30c reduces hyperlipidemia and atherosclerosis in mice by decreasing lipid synthesis and lipoprotein secretion. Nat Med. 2013;19(7):892–900. doi:10.1038/nm.3200. An elegant example of how miR-30c controls LDL cholesterol levels by targeting MTP, yet concomitantly reduces lipid synthesis by targeting LPGAT1, revitalizing hope for miR-30c as an MTP-targeting therapy for hypercholesterolemia.PubMedPubMedCentralCrossRef

29.

Care A, Catalucci D, Felicetti F, Bonci D, Addario A, Gallo P, et al. MicroRNA-133 controls cardiac hypertrophy. Nat Med. 2007;13(5):613–18. doi:10.1038/nm1582.PubMedCrossRef

30.

Matkovich SJ, Wang W, Tu Y, Eschenbacher WH, Dorn LE, Condorelli G, et al. MicroRNA-133a protects against myocardial fibrosis and modulates electrical repolarization without affecting hypertrophy in pressure-overloaded adult hearts. Circ Res. 2010;106(1):166–75. doi:10.1161/CIRCRESAHA.109.202176.PubMedCrossRef

31.

Liu N, Bezprozvannaya S, Williams AH, Qi X, Richardson JA, Bassel-Duby R, et al. microRNA-133a regulates cardiomyocyte proliferation and suppresses smooth muscle gene expression in the heart. Genes Dev. 2008;22(23):3242–54. doi:10.1101/gad.1738708.PubMedPubMedCentralCrossRef

32.

Dong S, Ma W, Hao B, Hu F, Yan L, Yan X, et al. microRNA-21 promotes cardiac fibrosis and development of heart failure with preserved left ventricular ejection fraction by up-regulating Bcl-2. Int J Clin Exp Pathol. 2014;7(2):565–74.PubMedPubMedCentral

33.

Thum T, Gross C, Fiedler J, Fischer T, Kissler S, Bussen M, et al. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature. 2008;456(7224):980–4. doi:10.1038/nature07511.PubMedCrossRef

34.

Kumarswamy R, Volkmann I, Jazbutyte V, Dangwal S, Park D-H, Thum T. Transforming growth factor-β-induced endothelial-to-mesenchymal transition is partly mediated by microRNA-21. Arterioscler, Thromb, Vasc Biol. 2012;32(2):361–9. doi:10.1161/ATVBAHA.111.234286.CrossRef

35.

Patrick DM, Montgomery RL, Qi X, Obad S, Kauppinen S, Hill JA, et al. Stress-dependent cardiac remodeling occurs in the absence of microRNA-21 in mice. J Clin Invest. 2010;120(11):3912–16. doi:10.1172/JCI43604.PubMedPubMedCentralCrossRef

36.

Montgomery RL, Hullinger TG, Semus HM, Dickinson BA, Seto AG, Lynch JM, et al. Therapeutic inhibition of miR-208a improves cardiac function and survival during heart failure. Circulation. 2011;124(14):1537–47. doi:10.1161/CIRCULATIONAHA.111.030932.

37.

Callis TE, Pandya K, Seok HY, Tang R-h, Tatsuguchi M, Huang Z-p, et al. MicroRNA-208a is a regulator of cardiac hypertrophy and conduction in mice. J Clin Investig. 2009;119(9):2772–86. doi:10.1172/JCI36154.2772.PubMedPubMedCentralCrossRef

38.

van Rooij E, Sutherland LB, Qi X, Richardson JA, Hill J, Olson EN. Control of stress-dependent cardiac growth and gene expression by a microRNA. Science. 2007;316(5824):575–9. doi:10.1126/science.1139089.PubMedCrossRef

39.•

Grueter CE, van Rooij E, Johnson BA, DeLeon SM, Sutherland LB, Qi X, et al. A cardiac microRNA governs systemic energy homeostasis by regulation of MED13. Cell. 2012;149(3):671–83. doi:10.1016/j.cell.2012.03.029. An example of how a tissue-specific miRNA can regulate whole-body energy metabolism by targeting genes in the heart.PubMedPubMedCentralCrossRef

40.

da Costa Martins PA, Salic K, Gladka MM, Armand AS, Leptidis S, el Azzouzi H, et al. MicroRNA-199b targets the nuclear kinase Dyrk1a in an auto-amplification loop promoting calcineurin/NFAT signalling. Nat Cell Biol. 2010;12(12):1220–7. doi:10.1038/ncb2126.PubMedCrossRef

41.

Bang C, Fiedler J, Thum T. Cardiovascular importance of the microRNA-23/27/24 family. Microcirculation (New York, NY: 1994). 2012;19(3):208–14. doi:10.1111/j.1549-8719.2011.00153.CrossRef

42.

Zhou Q, Gallagher R, Ufret-Vincenty R, Li X, Olson EN, Wang S. Regulation of angiogenesis and choroidal neovascularization by members of microRNA-23-27-24 clusters. Proc Natl Acad Sci U S A. 2011;108(20):8287–92. doi:10.1073/pnas.1105254108.

43.

Fiedler J, Jazbutyte V, Kirchmaier BC, Gupta SK, Lorenzen J, Hartmann D, et al. MicroRNA-24 regulates vascularity after myocardial infarction. Circulation. 2011;124(6):720–30. doi:10.1161/CIRCULATIONAHA.111.039008.PubMedCrossRef

44.

Qian L, Van Laake LW, Huang Y, Liu S, Wendland MF, Srivastava D. miR-24 inhibits apoptosis and represses Bim in mouse cardiomyocytes. J Exp Med. 2011;208(3):549–60. doi:10.1084/jem.20101547.PubMedPubMedCentralCrossRef

45.

Wang S, Olson EN. AngiomiRs—key regulators of angiogenesis. Curr Opin Genet Dev. 2009;19(3):205–11. doi:10.1016/j.gde.2009.04.002.PubMedPubMedCentralCrossRef

46.

Wu W, Xiao H, Laguna-Fernandez A, Villarreal Jr G, Wang KC, Geary GG, et al. Flow-dependent regulation of Kruppel-like factor 2 is mediated by microRNA-92a. Circulation. 2011;124(5):633–41. doi:10.1161/CIRCULATIONAHA.110.005108.PubMedCrossRef

47.

Bonauer A, Carmona G, Iwasaki M, Mione M, Koyanagi M, Fischer A, et al. MicroRNA-92a controls angiogenesis and functional recovery of ischemic tissues in mice. Science. 2009;324(5935):1710–13. doi:10.1126/science.1174381.PubMedCrossRef

48.

Loyer X, Potteaux S, Vion A-C, Guérin CL, Boulkroun S, Rautou P-E, et al. Inhibition of microRNA-92a prevents endothelial dysfunction and atherosclerosis in mice. Circ Res. 2014;114(3):434–43. doi:10.1161/CIRCRESAHA.114.302213.PubMedCrossRef

49.

Hinkel R, Penzkofer D, Zühlke S, Fischer A, Husada W, Xu Q-F, et al. Inhibition of microRNA-92a protects against ischemia/reperfusion injury in a large-animal model. Circulation. 2013;128(10):1066–75. doi:10.1161/CIRCULATIONAHA.113.001904.PubMedCrossRef

50.

Zhu H, Fan G-C. Role of microRNAs in the reperfused myocardium towards post-infarct remodelling. Cardiovasc Res. 2012;94(2):284–92. doi:10.1093/cvr/cvr291.PubMedCrossRef

51.

Fish JE, Santoro MM, Morton SU, Yu S, Yeh RF, Wythe JD, et al. miR-126 regulates angiogenic signaling and vascular integrity. Dev Cell. 2008;15(2):272. doi:10.1016/j.devcel.2008.07.008.

52.

Wang S, Aurora AB, Johnson BA, Qi X, McAnally J, Hill JA, et al. The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis. Dev Cell. 2008;15(2):261–71. doi:10.1016/j.devcel.2008.07.002.PubMedPubMedCentralCrossRef

53.

Harris TA, Yamakuchi M, Ferlito M, Mendell JT, Lowenstein CJ. MicroRNA-126 regulates endothelial expression of vascular cell adhesion molecule 1. Proc Natl Acad Sci U S A. 2008;105(5):1516–21. doi:10.1073/pnas.0707493105.PubMedPubMedCentralCrossRef

54.

Zernecke A, Bidzhekov K, Noels H, Shagdarsuren E, Gan L, Denecke B, et al. Delivery of microRNA-126 by apoptotic bodies induces CXCL12-dependent vascular protection. Sci Signal. 2009;2(100):ra81. doi:10.1126/scisignal.2000610.PubMedCrossRef

55.••

Schober A, Nazari-Jahantigh M, Wei Y, Bidzhekov K, Gremse F, Grommes J, et al. MicroRNA-126-5p promotes endothelial proliferation and limits atherosclerosis by suppressing Dlk1. Nat Med. 2014;20(4):368–76. doi:10.1038/nm.3487. This work is the first to describe how different “arms” of a mature microRNA, -3p versus -5p, can have divergent functions in regulating endothelial function in atherosclerosis.PubMedPubMedCentralCrossRef

56.

Xin M, Small EM, Sutherland LB, Qi X, McAnally J, Plato CF, et al. MicroRNAs miR-143 and miR-145 modulate cytoskeletal dynamics and responsiveness of smooth muscle cells to injury. Genes Dev. 2009;23(18):2166–78. doi:10.1101/gad.1842409.PubMedPubMedCentralCrossRef

57.

Cheng Y, Liu X, Yang J, Lin Y, Xu D-Z, Lu Q, et al. MicroRNA-145, a novel smooth muscle cell phenotypic marker and modulator, controls vascular neointimal lesion formation. Circ Res. 2009;105(2):158–66. doi:10.1161/CIRCRESAHA.109.197517.PubMedPubMedCentralCrossRef

58.

Boettger T, Beetz N, Kostin S, Schneider J, Kruger M, Hein L, et al. Acquisition of the contractile phenotype by murine arterial smooth muscle cells depends on the Mir143/145 gene cluster. J Clin Invest. 2009;119(9):2634–47. doi:10.1172/JCI38864.PubMedPubMedCentralCrossRef

59.

Lovren F, Pan Y, Quan A, Singh KK, Shukla PC, Gupta N, et al. MicroRNA-145 targeted therapy reduces atherosclerosis. Circulation. 2012;126(11 Suppl 1):S81–90. doi:10.1161/CIRCULATIONAHA.111.084186.PubMed

60.

O'Connell RM, Taganov KD, Boldin MP, Cheng G, Baltimore D. MicroRNA-155 is induced during the macrophage inflammatory response. Proc Natl Acad Sci U S A. 2007;104(5):1604–9. doi:10.1073/pnas.0610731104.PubMedPubMedCentralCrossRef

61.

Graff JW, Dickson AM, Clay G, McCaffrey AP, Wilson ME. Identifying functional microRNAs in macrophages with polarized phenotypes. J Biol Chem. 2012;287(26):21816–25. doi:10.1074/jbc.M111.327031.PubMedPubMedCentralCrossRef

62.

Nazari-Jahantigh M, Wei Y, Noels H, Akhtar S, Zhou Z, Koenen RR, et al. MicroRNA-155 promotes atherosclerosis by repressing Bcl6 in macrophages. J Clin Invest. 2012;122(11):4190–202. doi:10.1172/JCI61716.PubMedPubMedCentralCrossRef

63.

Du F, Yu F, Wang Y, Hui Y, Carnevale K, Fu M, et al. MicroRNA-155 deficiency results in decreased macrophage inflammation and attenuated atherogenesis in apolipoprotein E-deficient mice. Arterioscler, Thromb, Vasc Biol. 2014;34(4):759–67. doi:10.1161/ATVBAHA.113.302701.CrossRef

64.

Donners MM, Wolfs IM, Stoger LJ, van der Vorst EP, Pottgens CC, Heymans S, et al. Hematopoietic miR155 deficiency enhances atherosclerosis and decreases plaque stability in hyperlipidemic mice. PLoS One. 2012;7(4):e35877. doi:10.1371/journal.pone.0035877.PubMedPubMedCentralCrossRef

65.

Wei Y, Nazari-Jahantigh M, Chan L, Zhu M, Heyll K, Corbalan-Campos J, et al. The microRNA-342-5p fosters inflammatory macrophage activation through an Akt1- and microRNA-155-dependent pathway during atherosclerosis. Circulation. 2013. doi:10.1161/CIRCULATIONAHA.112.000736.

66.

Taganov KD, Boldin MP, Chang KJ, Baltimore D. NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci U S A. 2006;103(33):12481–6. doi:10.1073/pnas.0605298103.PubMedPubMedCentralCrossRef

67.

Chassin C, Kocur M, Pott J, Duerr CU, Gütle D, Lotz M, et al. miR-146a mediates protective innate immune tolerance in the neonate intestine. Cell Host Microbe. 2010;8(4):358–68. doi:10.1016/j.chom.2010.09.005.PubMedCrossRef

68.

Perry MM, Sa M, Williams AE, Shepherd NJ, Larner-Svensson HM, Lindsay M. Rapid changes in microRNA-146a expression negatively regulate the IL-1-induced inflammatory response in human lung alveolar epithelial cells. J Immunol. 2008;180(8):5689–98. doi:10.4049/jimmunol.180.8.5689.

69.

Boldin MP, Taganov KD, Rao DS, Yang L, Zhao JL, Kalwani M, et al. miR-146a is a significant brake on autoimmunity, myeloproliferation, and cancer in mice. J Exp Med. 2011;208(6):1189–201. doi:10.1084/jem.20101823.PubMedPubMedCentralCrossRef

70.

Cheng HS, Sivachandran N, Lau A, Boudreau E, Zhao JL, Baltimore D, et al. MicroRNA-146 represses endothelial activation by inhibiting pro-inflammatory pathways. EMBO Mol Med. 2013;5(7):949–66. doi:10.1002/emmm.201202318.PubMedCentralCrossRef

71.

Wei Y, Nazari-Jahantigh M, Neth P, Weber C, Schober A. MicroRNA-126, -145, and -155: a therapeutic triad in atherosclerosis? Arterioscler, Thromb, Vasc Biol. 2013;33(3):449–54. doi:10.1161/ATVBAHA.112.300279.CrossRef

72.

Chen X, Liang H, Zhang J, Zen K, Zhang C-Y. Secreted microRNAs: a new form of intercellular communication. Trends Cell Biol. 2012;22(3):125–32. doi:10.1016/j.tcb.2011.12.001.PubMedCrossRef

73.

Rayner KJ, Hennessy EJ. Extracellular communication via microRNA: lipid particles have a new message. J Lipid Res. 2013;54(5):1174–81. doi:10.1194/jlr.R034991.PubMedPubMedCentralCrossRef

74.

Vickers KC, Palmisano BT, Shoucri BM, Shamburek RD, Remaley AT. MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nature cell biology. 2011;13(4):423–33. doi:10.1038/ncb2210.PubMedPubMedCentralCrossRef

75.

Ra B, Vickers KC. Intercellular transport of microRNAs. Arterioscler, Thromb, Vasc Biol. 2013;33(2):186–92. doi:10.1161/ATVBAHA.112.300139.CrossRef

76.•

Hergenreider E, Heydt S, Treguer K, Boettger T, Horrevoets AJ, Zeiher AM, et al. Atheroprotective communication between endothelial cells and smooth muscle cells through miRNAs. Nat Cell Biol. 2012;14(3):249–56. doi:10.1038/ncb2441. One of the first examples of how extracellular miRNAs facilitate communication between neighboring cells during the progression of cardiovascular disease.PubMedCrossRef

77.

Halkein J, Tabruyn SP, Ricke-hoch M, Haghikia A, Nguyen N-q-n, Scherr M, et al. MicroRNA-146a is a therapeutic target and biomarker for peripartum cardiomyopathy. J Clin Invest. 2013;123(5):2143–54. doi:10.1172/JCI64365. PubMedPubMedCentralCrossRef

78.

Zhang Y, Liu D, Chen X, Li J, Li L, Bian Z, et al. Secreted monocytic miR-150 enhances targeted endothelial cell migration. Mol Cell. 2010;39(1):133–44. doi:10.1016/j.molcel.2010.06.010.PubMedCrossRef

79.

Chen L, Wang Y, Pan Y, Zhang L, Shen C, Qin G, et al. Cardiac progenitor-derived exosomes protect ischemic myocardium from acute ischemia/reperfusion injury. Biochem Biophys Res Commun. 2013;431(3):566–71. doi:10.1016/j.bbrc.2013.01.015.PubMedPubMedCentralCrossRef

80.

Alvarez-Erviti L, Seow Y, Yin H, Betts C, Lakhal S, Wood MJ. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat Biotechnol. 2011;29(4):341–5. doi:10.1038/nbt.1807.CrossRefPubMed

81.

Development of new therapeutic drugs and biologics for rare diseases. In: Field MJ, Boat TJ, editors. Rare diseases and orphan products: accelerating research and development. Development of New Therapeutic Drugs and Biologics for Rare Diseases. Washington, D.C.: THE NATIONAL ACADEMIES PRESS (2010).

82.

Brown WV, Rader DJ, Goldberg AC. JCL roundtable: drug treatment of severe forms of familial hypercholesterolemia. J Clin Lipidol. 2014;8(1):10–7. doi:10.1016/j.jacl.2013.09.004.PubMedCrossRef

83.

Fichtlscherer S, De Rosa S, Fox H, Schwietz T, Fischer A, Liebetrau C, et al. Circulating microRNAs in patients with coronary artery disease. Circ Res. 2010;107(5):677–84. doi:10.1161/CIRCRESAHA.109.215566.

84.

Hoekstra M, van der Lans CA, Halvorsen B, Gullestad L, Kuiper J, Aukrust P, et al. The peripheral blood mononuclear cell microRNA signature of coronary artery disease. Biochem Biophys Res Commun. 2010;394(3):792–7. doi:10.1016/j.bbrc.2010.03.075.

85.

Wang GK, Zhu JQ, Zhang JT, Li Q, Li Y, He J, et al. Circulating microRNA: a novel potential biomarker for early diagnosis of acute myocardial infarction in humans. Eur Heart J. 2010;31(6):659–66. doi:10.1093/eurheartj/ehq013.

86.

Adachi T, Nakanishi M, Otsuka Y, Nishimura K, Hirokawa G, Goto Y, et al. Plasma microRNA-499 as a biomarker of acute myocardial infarction. Clin Chem. 2010;56(7):1183–5. doi:10.1373/clinchem.2010.144121.

87.

D’Alessandra Y, Devanna P, Limana F, Straino S, Di Carlo A, Brambilla PG, et al. Circulating microRNAs are new and sensitive biomarkers of myocardial infarction. Eur Heart J. 2010;31(22):2765–73. doi:10.1093/eurheartj/ehq167.

88.

Corsten MF, Dennert R, Jochems S, Kuznetsova T, Devaux Y, Hofstra L, et al. Circulating microRNA-208b and microRNA-499 reflect myocardial damage in cardiovascular disease. Circ Cardiovasc Genet. 2010;3(6):499–506. doi:10.1161/CIRCGENETICS.110.957415.

89.

Cheng Y, Tan N, Yang J, Liu X, Cao X, He P, et al. A translational study of circulating cell-free microRNA-1 in acute myocardial infarction. Clin Sci (Lond). 2010;119(2):87–95. doi:10.1042/CS20090645.

90.

Long G, Wang F, Duan Q, Yang S, Chen F, Gong W, et al. Circulating miR-30a, miR-195 and let-7b associated with acute myocardial infarction. PloS One. 2012;7(12):e50926. doi:10.1371/journal.pone.0050926.

91.

Voellenkle C, van Rooij J, Cappuzzello C, Greco S, Arcelli D, Di Vito L, et al. MicroRNA signatures in peripheral blood mononuclear cells of chronic heart failure patients. Physiol Genomics. 2010;42(3):420–6. doi:10.1152/physiolgenomics.00211.2009.

92.

Fukushima Y, Nakanishi M, Nonogi H, Goto Y, Iwai N. Assessment of plasma miRNAs in congestive heart failure. Circ J. 2011;75(2):336–340. doi:10.1253/circj.CJ-10-0457.

93.

Tijsen AJ, Creemers EE, Moerland PD, de Windt LJ, van der Wal AC, Kok WE, Pinto YM. MiR423-5p as a circulating biomarker for heart failure. Circ Res. 2010;106(6):1035–9. doi:10.1161/CIRCRESAHA.110.218297.

94.

Goren Y, Kushnir M, Zafrir B, Tabak S, Lewis BS, Amir O. Serum levels of microRNAs in patients with heart failure. Eur J Heart Fail. 2012;14(2):147–54. doi:10.1093/eurjhf/hfr155.

95.

Fan KL, Zhang HF, Shen J, Zhang Q, Li XL. Circulating microRNAs levels in Chinese heart failure patients caused by dilated cardiomyopathy. Indian Heart J. 2013;65(1), 12–6. doi:10.1016/j.ihj.2012.12.022.

Titel: Unlocking the Door to New Therapies in Cardiovascular Disease: MicroRNAs Hold the Key
verfasst von: My-Anh Nguyen
Denuja Karunakaran
Katey J Rayner
Publikationsdatum: 01.11.2014
Verlag: Springer US
Erschienen in: Current Cardiology Reports / Ausgabe 11/2014
Print ISSN: 1523-3782
Elektronische ISSN: 1534-3170
DOI: https://doi.org/10.1007/s11886-014-0539-7

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Unlocking the Door to New Therapies in Cardiovascular Disease: MicroRNAs Hold the Key

Abstract

Neu im Fachgebiet Kardiologie

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

Update Kardiologie

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2014

Electronic Cigarettes for Smoking Cessation

Where and when Device Therapy May Be Useful in the Management of Drug-Resistant Hypertension

Far from the Eyes, Close to the Heart: Dysbiosis of Gut Microbiota and Cardiovascular Consequences

Evaluating Cardiovascular Safety of Novel Therapeutic Agents for the Treatment of Type 2 Diabetes Mellitus

Nonatherosclerotic Causes of Acute Coronary Syndrome: Recognition and Management

New Developments in the Management of Neurogenic Orthostatic Hypotension

Neu im Fachgebiet Kardiologie

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

Update Kardiologie